Ninety-year-old nursing home resident Margaret Keenan received the first of two doses of a vaccine jointly developed by U.S.-based pharmaceutical giant Pfizer and Germany’s BioNTech.
The vaccination campaign, dubbed “V-Day” by Health Secretary Mark Hancock, began nearly a week after the government’s medical regulatory agency granted emergency approval for the vaccine, making Britain the first western nation ready to begin mass inoculations.
The approval came weeks after Pfizer announced the vaccine had been shown to be more than 90% effective after its final clinical trial.
Keenan, who will turn 91 next week, is among the thousands of nursing home residents and their caregivers, along with staffers with Britain’s National Health Service, that have been prioritized by officials to receive the first shots.
Britain received 800,000 doses of the Pfizer/BioNTech vaccine Sunday, the first of a total of 40 million it purchased from Pfizer. Great Britain has a population of more than 66 million people. Delivery of the vaccine is complicated by the fact that it must be stored in super-cold refrigerators at temperatures below 70 degrees Celsius.
Britain has recorded more than 61,000 deaths since the start of the pandemic, one of the world’s hardest-hit countries and the worst affected country in Europe.
*Reuters/VOA
0